Description
Serum thymic factor (FTS) is a synthetic nonapeptide hormone that exhibits anti-apoptotic, anti-diabetic, anti-inflammatory, and immunomodulatory activities. In vivo, FTS increases activity of superoxide dismutase (SOD) and decreases activation of ERK, inhibiting cephaloridine-induced kidney damage and dysfunction. In other animal models, FTS increases expression of Bcl-2 and IL-6, preventing LPS-induced damage to pancreatic cells. FTS also suppresses the symptoms of experimental autoimmune encephalitis (EAE) in animal models. In vitro, this peptide increases T cell differentiation and activates T cells and NK cells. In vivo, FTS prevents the viral induction of diabetes, preventing loss of insulin granules, myocardial inflammation, and pancreatic islet cell necrosis.
References
Kohda Y, Matsunaga Y, Yonogi K, et al. Protective effect of serum thymic factor, FTS, on cephaloridine-induced nephrotoxicity in rats. Biol Pharm Bull. 2005 Nov;28(11):2087-91. PMID: 16272694.
Saitoh N, Awaya A, Sakudo A, et al. Serum thymic factor prevents LPS-induced pancreatic cell damage in mice via up-regulation of Bcl-2 expression in pancreas. Microbiol Immunol. 2004;48(9):629-38. PMID: 15383698.
Mizutani M, El-Fotoh M, Mori M, et al. In vivo administration of serum thymic factor (FTS) prevents EMC-D virus-induced diabetes and myocarditis in BALB/cAJcl mice. Arch Virol. 1996;141(1):73-83. PMID: 8629952.
Kato S, Nakamura H. Suppression of acute experimental allergic encephalomyelitis by synthetic serum thymic factor. Clinical, histopathological, and immunohistochemical studies. Acta Neuropathol. 1988;75(4):337-44. PMID: 2834909.
Kaiserlian D, Bardos P, Bach JF. In vitro modulation of mouse natural killer (NK) cell activity by the serum thymic factor (FTS). Cell Immunol. 1983 Mar;76(2):232-42. PMID: 6682352.
